Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactitol + Lactobacillus acidophilus + Bifidobacterium bifidum
- Development stage
- Unknown
- Lead developer
- FIBHULP
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination therapy, evaluated in the DesProbiOXA pilot study (NCT02307383), consists of the prebiotic lactitol (Emportal) and a probiotic mixture (Infloran) containing *Lactobacillus acidophilus* and *Bifidobacterium bifidum*. Developed by the Instituto de Investigación Hospital Universitario La Paz, it is designed for the intestinal decolonization of carriers of OXA-48-producing *Klebsiella pneumoniae*. The mechanism of action involves the modulation of the gastrointestinal microbiota to reduce the colonization of carbapenem-resistant Enterobacteriaceae through competitive exclusion and the promotion of a non-permissive environment for antibiotic-resistant strains. The proof-of-concept trial demonstrated that the combination was well-tolerated and resulted in a rapid reduction of intestinal loads of OXA-48-producing bacteria.
- Brand names
- EmportalInfloran
- Other names
- Lactitol and ProbioticsLactitol + Lactobacillus acidophilus + Lactobacillus bifidusDesProbiOXA intervention
Beyond the preview
Go deeper on lactitol + Lactobacillus acidophilus + Bifidobacterium bifidum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactitol + Lactobacillus acidophilus + Bifidobacterium bifidum.